The objective of this pilot study was to assess a 2-year change in innate immune burden in 15 progressive multiple sclerosis (MS) patients using PK11195-PET. Sixteen age-matched healthy controls (HC) were included for baseline comparison. PK11195 uptake was higher in MS patients compared to HC within normal-appearing white matter (NAWM) and multiple gray matter regions. In patients, PK11195 uptake increased in NAWM (p = 0.01), cortex (p = 0.04), thalamus (p = 0.04), and putamen (p = 0.02) at 12 months. Among patients remaining at 24 months, there was no further increase in PK11195. Our data suggest that innate immune activity may increase over time in patients with progressive MS.

中文翻译：

---

进行性多发性硬化中 TSPO PET 成像的纵向变化

这项试点研究的目的是使用 PK11195-PET 评估 15 名进行性多发性硬化 (MS) 患者的先天免疫负担 2 年变化。包括 16 名年龄匹配的健康对照 (HC) 用于基线比较。与 HC 相比，在外观正常的白质 (NAWM) 和多个灰质区域内，MS 患者的 PK11195 摄取更高。在患者中，12 个月时，NAWM ( p  = 0.01)、皮质 ( p  = 0.04)、丘脑 ( p  = 0.04) 和壳核 ( p  = 0.02) 的PK11195 摄取增加。在剩余 24 个月的患者中，PK11195 没有进一步增加。我们的数据表明，进行性 MS 患者的先天免疫活性可能会随着时间的推移而增加。